FDA Approves Obecabtagene Autoleucel for Adults with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukaemia By Ogkologos - December 3, 2024 954 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the FELIX study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Higher Pregnancy Rates and No Impact on Prognosis with Embryo/Oocyte Cryopreservation... June 26, 2024 Sisters on Opposite Sides of the Country Diagnosed with Breast Cancer... December 16, 2020 Artificial Intelligence Expedites Brain Tumor Diagnosis during Surgery February 12, 2020 Advancing Patient Care Through Focused Innovation April 16, 2018 Load more HOT NEWS One Family’s Mission to Stop Hair Loss from Chemotherapy: Your Stories... New tool to tackle gaps in public’s knowledge of blood cancer... Italian Association of Oncology Nurses Maps the Situation of Cancer Patients... Man Becomes Nervous About How Cop Acts During Ticket, Then He...
